Topical minocycline foam 4%: Results of four phase 1 studies evaluating the potential for phototoxicity, photoallergy, sensitization, and cumulative irritation
FMX101 4% contains 4% micronized minocycline (as an HCl) formulated in a lipophilic foam vehicle for topical administration. FMX101 4% has been shown to be an effective and well-tolerated treatment for moderate-to-severe acne in three Phase 3 pivotal studies, however, skin sensitization and toxicity...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Taylor & Francis Group
2019-01-01
|
| Seri Bilgileri: | Journal of Immunotoxicology |
| Konular: | |
| Online Erişim: | http://dx.doi.org/10.1080/1547691X.2019.1610117 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|